Dating and Relationships While Living with MBC
As with many aspects of life, romantic, family, friends, and other types of relationships can be challenging when living with MBC. Read below for stories and...
Read MoreNew Clinical Trials For Stage IV Breast Cancer
We added the following clinical trials to Metastatic Trial Search for December 2024. To see all clinical trials, please visit Metastatic Trial Search. ER or PR...
Read MoreWhat to Know About MBC Treatment-Related Heart Problems
Some breast cancer treatments like radiation, chemotherapy, and targeted therapy, such as trastuzumab (Herceptin®), can cause or increase the risk of heart...
Read MoreASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
In 2021, sacituzumab govitecan (Trodelvy®) was approved by the FDA to treat people with triple-negative MBC. In February 2023, the FDA expanded the approval of...
Read MoreWhat are Non-Treatment Trials and Why are They Important?
When most people think of clinical trials, they think of trials that test new drugs and drug combinations. However, clinical trials also study ways to improve...
Read MoreBlack Wo(Men) Speak Symposium 2022
The Black Wo(Men) Speak Symposium was held before SABCS on December 5, 2022. The goal of the symposium was to highlight the need for increased diversity in...
Read MoreFDA Approves Orserdu and Expands Approval of Trodelvy®
On January 27, 2023, the FDA approved elacestrant (OrserduTM, Stemline Therapeutics, Inc.) and a companion diagnostic test for the treatment of people with...
Read MoreNew ESR1 Biomarker Research Leads to FDA Approval for ER+, HER2- MBC with an ESR1 Mutation
At the end of January 2023, the FDA approved a new drug called elacestrant (OrserduTM) for people with estrogen receptor-positive, HER2-negative MBC with an ESR1...
Read MoreWhat is Stable Disease and How is it Monitored?
Stable disease means your treatments are causing your tumor(s) to either not grow or shrink while no new tumors are developing. If you have stable disease, you...
Read MoreSEARCH OUR SITE
for past articles or specific information.